Company Description
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals.
It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories.
The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services.
Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision.
The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers.
It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products.
The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand.
Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
| Country | United States |
| Founded | 1931 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 60,000 |
| CEO | David Shafer |
Contact Details
Address: One Baxter Parkway Deerfield, Illinois 60015 United States | |
| Phone | 224 948 2000 |
| Website | baxter.com |
Stock Details
| Ticker Symbol | BAX |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000010456 |
| CUSIP Number | 071813109 |
| ISIN Number | US0718131099 |
| Employer ID | 36-0781620 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David Brent Shafer | Chair and Interim Chief Executive Officer |
| Joel T. Grade | Executive Vice President and Chief Financial Officer |
| Heather Knight | Executive Vice President and Chief Operating Officer |
| Jose E. Almeida | Advisor |
| Alok Sonig B.E., Mba | Executive Vice President and Group President of Pharmaceuticals |
| Anita A. Zielinski | Senior Vice President, Chief Accounting Officer and Controller |
| Tobi Karchmer M.D., M.S. | Senior Vice President and Chief Medical and Scientific Officer |
| Charles Rusty Patel | Senior Vice President and Chief Information Officer |
| Clare Trachtman | Vice President of Investor Relations |
| David S. Rosenbloom | Executive Vice President and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | ARS | Filing |
| Mar 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 7, 2025 | SCHEDULE 13G/A | Filing |
| Mar 3, 2025 | EFFECT | Notice of Effectiveness |
| Feb 25, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Feb 21, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |